Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1144-1151

  Kamiñska, Katarzyna ^a   Goembiowska, Krystyna ^a   Rogóz, Zofia ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Dopamine; Fluoxetine; Rats; Risperidone; Serotonin or noradrenaline release

Indexed keywords

DOPAMINE; FLUOXETINE; NORADRENALIN; RISPERIDONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG POTENTIATION; EXTRACELLULAR SPACE; FRONTAL CORTEX; MALE; MICRODIALYSIS; MONOTHERAPY; NONHUMAN; NORADRENALIN RELEASE; RAT; SEROTONIN RELEASE; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DRUG INTERACTIONS; FLUOXETINE; MALE; MICRODIALYSIS; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 84894127557     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71472-5     Document Type: Article

References (59)

1. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386. (Pubitemid 26184108)
2. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P: The effect of fluoxetine on the pharmacokinetic and safety of risperidone in psychotic patients. Pharmacopsychiatry, 2002, 35, 50-56. (Pubitemid 34293233)
3. Burda K, Czubak A, Kuoe K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
4. Bymaster FP, Rasmussen K, Calligare DO, Nelson DL, DeLapp N, Wong DT, Moore NA: In vitro and in vivo biochemistry of olanzapine: A novel atypical antipsychotic drug. J Clin Psychiatry, 1997, 58, 28-36. (Pubitemid 27333178)
5. Bymaster FP, Zhong W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW: Fluoxetine, but not other selective serotonin uptake inhibitors, increases noradrenaline and dopamine extracellular levels in pre-frontal cortex. Psychopharmacology (Berl), 2002, 160, 353-361. (Pubitemid 34253277)
6. Carboni E, Tanda GL, Frau R, Di Chiara G: Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem, 1990, 55, 1067-1070.
7. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
8. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possible induction of rat CYP2D after short-and longterm treatment with antidepressants. J Pharm Pharmacol, 2002, 54, 1545-1552. (Pubitemid 35331216)
9. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
10. Dremenkov E, Mansari EM, Blier P: Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry, 2007, 61, 671-678. (Pubitemid 46328857)
11. Dreshfield LJ, Wong DT, Perry KW, Engleman EA: Enhancement of fluoxetine dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res, 1996, 21, 557-562.
12. Felton TM, Kang TB, Hjorth S, Auerbach SB: Effect of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalons and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol, 2003, 367, 297-305. (Pubitemid 36408012)
13. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L,MillanMJ: Stimultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of free-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor mediated control release. Neuroscience, 1998, 84, 413-429. (Pubitemid 28122907)
14. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ: Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonine levels in the prefrontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenergic receptors underling its actions. Neuroscience, 1999, 93, 1251-1262. (Pubitemid 29397553)
15. Hertel P, Fagerquist MV, Svensson TH: Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science, 1999, 286, 105-107. (Pubitemid 29484485)
16. Hertel P, Nomikos GG, Iurlo M, Svensson TH: Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology, 1996, 124, 74-86. (Pubitemid 26112776)
17. Hertel P, Nomikos GG, Schilstrom B, Arborelius L, Svensson TH: Risperidone dose-dependently increases extracellular concentrations of serotoninin the rat frontal cortex: Role of α2-adrenoreceptors antagonism. Neuropsychopharmacology, 1997, 17, 44-55. (Pubitemid 27259712)
18. Hirose S, Ashby CR: An open pilot study combining risperidone and selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry, 2002, 63, 733-736.
19. Huang M, Ichiwara J, Li Z, Dai J, Meltzer HY: Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology, 2006, 185, 274-281.
20. Ichikawa J, Kuroki T, Dai J, Meltzer HY: Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol, 1998, 351, 163-171. (Pubitemid 28312927)
21. Iyer RN, Bradberry CW: Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther, 1996, 277, 40-47. (Pubitemid 27169041)
22. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F: In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse, 1994, 18, 294-297. (Pubitemid 24357828)
23. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebocontrolled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
24. Koch S, Perry KW, Bymaster FP: Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology, 2004, 46, 232-242. (Pubitemid 37532831)
25. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP: R-fluoxetine increases extracellular DA, NA, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology, 2002, 27, 949-959. (Pubitemid 35447632)
26. Kumar R, Palit G, Dhawan BN: Comparative behavioral effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol, 2003, 462, 133-138. (Pubitemid 36183744)
27. Kuroki T, Meltzer HY, Ichikawa J: Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther, 1999, 288, 774-781. (Pubitemid 29119694)
28. Li XM, Perry KW, Wong DT, Bymaster FP: Olanzapine increases in vitro dopamine and noradrenaline release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology, 1998, 136, 153-161. (Pubitemid 28137955)
29. Maes M, Meltzer HY: The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 933-944.
30. Matsumoto M, Togashi H, Mori K, Ueno K, Miyamoto A, Yoshioka M: Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol, 1999, 383, 39-48. (Pubitemid 29509820)
31. Nowakowska E, Kuoe K, Polañski A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazapine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
32. O'Connor M, Silver H: Additing risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol, 1998, 18, 89-91. (Pubitemid 28045644)
33. Ostroff RB, Nelson J: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 1999, 60, 256-259. (Pubitemid 29193925)
34. Perry KW, Fuller RW: Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci, 1992, 50, 1683-1690.
35. Perry KW, Fuller RW: Fluoxetine increases noradrenaline release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rat. J Neural Transm, 1997, 104, 953-966. (Pubitemid 27507341)
36. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R: Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem, 1994, 63, 195-200. (Pubitemid 24184918)
37. Pozzi L, Invernizzi R, Garavagia C, Samanin R: Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J Neurochem, 1999, 73, 1051-1057. (Pubitemid 29395461)
38. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatmentresistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2006, 31, 2505-2513. (Pubitemid 44607069)
39. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
40. Rogó Z: Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
41. Rogó Z, Goembiowska K: Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex. Pharmacol Rep, 2010, 62, 1015-1022.
42. Rogó Z, Kabziñski M: Enhancement of the antiimmobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacol Rep, 2011, 63, 1533-1538.
43. Rogó Z, KabziñskiM, SadajW, Rachwalska P, Gdek-Michalska A: Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep, 2012, 64, 1391-1399.
44. Salmerón JM, Alcántara AG, Barcia D: Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder (Spanish). Actas Luco Esp Neurol Psiquiatr Cienc Afines, 1998, 26, 399-402.
45. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Med Neurobiol, 1999, 19, 467-489. (Pubitemid 29283825)
46. Schatzberg AF, Schildkraut J: Recent studies on norepinephrine systems in mood disorders. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 911-920.
47. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73. (Pubitemid 26112775)
48. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
49. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatry Scand, 2008, 117, 253-259. (Pubitemid 351350599)
50. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VI, Schmidt CJ: Characterization of 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther, 1993, 266, 684-691. (Pubitemid 23318678)
51. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E: Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinical relevant pharmacokinetic drug interaction. J Clin Psychopharmacol, 2002, 22, 419-423. (Pubitemid 34810333)
52. Spina E, Santoro V, in depression and mania. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 921-931.
53. Sprouse J, Clarke T, Reynolds L, Heym J, Rollema H: Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5HT reuptake in vivo. Neuropsychopharmacology, 1996, 14, 225-231. (Pubitemid 26120551)
54. Tanda G, Carboni E, Fran R, Di Chiara G: Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl), 1994, 115, 285-288. (Pubitemid 24207795)
55. Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F: BIMG 80, a novel potential antipsychotics drugs: Evidence for multireceptor actions and prefrontal release of dopamine in prefrontal cortex. J Neurochem, 1997, 69, 182-190. (Pubitemid 27274171)
56. Willner P: Dopaminergic mechanism in depression and mania. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 921-931.
57. Wright BM, Eiland III EH, Lorenz R: Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature. Pharmacotherapy, 2013, 33, 344-359.
58. Yoshino T, Nisijma K, Shioda K, Yui K, Katoh S: Perospirone, a novel atypical antipsychotic drugs, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett, 2004, 364, 16-21. (Pubitemid 38749189)
59. ZhangW, Perry KW,Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP: Synergistic effect of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 2000, 23, 250-262. (Pubitemid 30609659)